Summary. The 
Introduction
In mice, a thrombocytopaenic response (i.e. decrease in the concentration of circulating blood platelets) has been reported to occur as soon as 6 h after fertilization and to persist throughout the first week of pregnancy (O'Neill, 1985a) . A similar thrombocytopaenic response can be induced in nonpregnant mice by intraperitoneal administration of platelet-activating factor (PAF-acether; O'Neill, 1985c) . Both mouse and human preimplantation embryos between the zygote and the blastocyst stages are reported to release a potent platelet-activating factor Spinks & O'Neill, 1987; O'Neill et ai, 1987) , which has similar biochemical and biological properties to the ether phospholipid PAF-acether (O'Neill, 1985b) .
Platelet-activating factor has been quantitated in a bioassay using splenectomized mice of the Quackenbush strain (O'Neill et ai, 1985a; 1987) . Removal of the spleen is necessary because this organ acts as a reservoir for platelets and can release them into the circulation by splenic contrac¬ tion. This can mask reductions in the circulating platelet population and result in false negative responses in the bioassay (O'Neill, 1985c) .
Studies using antagonists of PAF have demonstrated the importance of embryo-derived PAF in the establishment of pregnancy in mice (Spinks & O'Neill, 1987 . In humans, the PAF pro¬ duction from in-vitro fertilized embryos, measured with the bioassay using Quackenbush mice, can be used to determine embryo viability prior to embryo transfer and to monitor embryo survival (O'Neill & Saunders, 1984; O'Neill et al, 1985b) . Such a quantitative method for the evaluation of embryonic viability would be of great benefit to the cattle embryo transfer industry, since the rate of loss of morphologically normal embryos following transfer is often >40% (Betteridge, 1986) .
However, since the Quackenbush mouse strain is not readily available in North America, and in the light of evidence concerning the insensitivity of platelets from some mouse strains to PAF (Namm et ai, 1982) , the present study was undertaken to determine whether PAF detection is possible using several more readily available strains of laboratory mice.
Materials and Methods

Experimental animals
Mice. Two random-bred mouse strains, Swiss Webster and CD1, and three inbred mouse strains, C3H/He, C57BL/6 and BALB/c, were obtained from Charles River Laboratories (St Constant, Quebec, Canada) Deep anaesthesia was achieved with an intraperitoneal injection of 0-2-0-5 ml of a 1-25% (w/v) tribromoethanol solution (Aldrich Chemical Company, Milwaukee, WI, USA). The mice remained unconscious for 0-5-1 -0 h.
For splenectomy, a left paramedial dorsal incision was performed on deeply anaesthetized 8-10-week-old mice. The spleen was drawn from the abdominal cavity with fine blunt forceps. The splenic blood vessels were electrocauterized and the organ was dissected free of adipose tissue and removed. The incision was sutured with 4-0 silk and the mice were placed under a heat lamp for recovery before being returned to normal housing conditions. Splenectomized mice were used in experiments 8-16 days after surgery.
Blood collection
Mice. Mice were lightly anaesthetized and blood was drawn from the retro-orbital plexus using 20-pl capillary tubes for the determination of platelet concentrations, 100-pl heparinized capillary tubes for haematocrit measure¬ ment, or siliconized Pasteur pipettes for collection of 0-5-1 ml volumes of blood. Blood collected by Pasteur pipette was prepared for platelet isolation by placing it into a 10 75 mm siliconized glass tube containing sodium citrate (12mM final concentration).
Cows and horses. Blood was collected from the jugular vein through a 14-gauge needle into a 50-ml sterile syringe containing sodium citrate (13mM final concentration). The blood was then placed into siliconized glass 5-ml conical tubes for platelet isolation.
Platelet isolation
Platelet-rich plasma (PRP) by Suquet & Leid (1983) .
Agents of platelet activation
Platelet-activating factor (PAF) . Purified preparations of PAF were obtained from three suppliers: 1-o-alkyl-2-acetyl-sn-glyceryl-3-phosphoryl-choline from Sigma, St Louis, MO. USA; l-o-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine from Boehringer-Mannheim, Dorval, Quebec, Canada and L-ot-lecithin.ß-acetyl.y-o-alkyl (Brecher & Cronkite, 1950 The effect of splenectomy on the detection of thrombocytopaenia during early pregnancy was studied in a similar manner, using 3 pregnant and 3 nonpregnant splenectomized female C57BL/6 mice.
Experiment 3a: evaluation of the splenectomized mouse bioassay Thirty Swiss Webster and 30 CD1 female mice were prepared for use in the PAF bioassay as described by O'Neill et al (1985a) . Briefly, a pre-injection control platelet concentration was determined for each splenectomized mouse. Syringes containing 200 pi of control vehicle (PBS-BSA) or PAF (2-3, 4-6 or 9-2pM) were prepared and coded so that their contents remained unknown until the end of the experiment. The content of each syringe was injected i.p. into an individual splenectomized mouse and a blood sample was obtained 30 min later. Each treatment was performed on 3 mice and the thrombocytopaenic effect was calculated for each animal by dividing post-injection by pre-injection platelet concentration and multiplying by 100.
Experiment 3b: estimation of changes in total numbers of circulating platelets during the splenectomized mouse bioassay Splenectomized Swiss Webster and CD 1 mice ( 10 of each strain) were used to measure platelet concentrations and haematocrits in sequential samples taken before and 30 min after 200-pl i.p. injections of either control vehicle or PAF (9-2pM; Boehringer-Mannheim). Each treatment was performed on 5 mice of each strain. The haematocrits were used to estimate changes in blood volume and to adjust the post-injection platelet concentration accordingly, so that changes in total numbers of circulating platelets could also be estimated. To do so, the post-injection platelet count was multiplied by the ratio of the pre-to post-injection haematocrits. The percentage change in total platelet numbers was then calculated by dividing corrected post-by pre-injection counts and multiplying by 100. The sensitivity of platelets from 5 mouse strains (Swiss Webster, CD1, C3H/He, C57BL/6, BALB/c) to PAF, ADP and thrombin was examined using a modified macroscopic haemagglutination procedure (Reisner et al, 1978 (Fig. 1 ). There was a trend, although not significant, for the platelet concentrations in pregnant animals to be lower than in nonpregnant animals in both Swiss Webster and C57BL/6 (P < 011, = 012, respectively). The mean number of embryos observed in the reproductive tracts of pregnant mice was 11-2 for Swiss Webster and 8-2 for C57BL/6.
When splenectomized C57BL/6 mice were examined over the same period, significant changes in platelet concentrations, with respect to time, were not detected. Furthermore, although differ¬ ences in the concentrations in pregnant and nonpregnant mice on any day were not significant, those in pregnant animals tended to be higher than in nonpregnant animals (P < 014; Fig. 2 ). The mean number of embryos observed in the reproductive tracts of pregnant mice was 7-3. Evaluation of the splenectomized mouse bioassay (Exp. 3a)
In the splenectomized mouse bioassay, none of the 3 PAF preparations at any concentration tested (2-3, 4-6 and 9-2µ ) induced a significant change in platelet concentrations with respect to either control or pre-injection concentrations in either strain of mouse used (Fig. 3) (Fig. 4) (Table 3) . None of the three prep¬ arations of PAF at either concentration aggregated isolated platelets. Both thrombin and ADP produced large platelet aggregates, while buffer controls had no effect on the platelets in the assay (Fig. 5, Table 3 ).
Discussion
The splenectomized mouse bioassay for the detection of PAF was developed using the Quackenbush strain of mouse (O'Neill et ai, 1985a) . Our study attempted to reproduce the bio¬ assay using more-common mouse strains. However, three purified sources of PAF which were shown to be potent in-vitro aggregators of cow and horse platelets were unable to induce a throm¬ bocytopaenic response in splenectomized mice of either the CD1 or Swiss Webster strain when given in doses comparable to those given to Quackenbush mice (O'Neill, 1985c 
that this could have been due to either genetic differences between mice or a lack of technical competence in platelet counting. Since Quackenbush mice were not available in this' laboratory, the genetic differences which might exist between this mouse strain and strains used in this study could not be examined. However, accuracy in platelet counting, the activity of the PAF preparations in other assays and the thrombocytopaenic response of the mice to agents other than PAF were each evaluated.
To rule out technical problems associated with the bioassay, the collection procedures for platelets were standardized, since variability in peripheral blood platelet concentrations > 5% is detrimental to the bioassay (O'Neill et ai, 1987) . Blood was collected in the same way from all mice from the retro-orbital plexus, and was not allowed to remain in ammonium oxalate for > 5 min prior to loading onto a haemocytometer. Platelet counting was performed by the same individual to eliminate observer variation. Replicate efficiency was acceptable, since the coefficient of vari¬ ation for platelet concentrations from 2 successive blood samples taken from one animal and (O'Neill, 1985a) .
The method of preparing the purified PAF for injection was identical to that described by O'Neill, (1985c) (1989) suggested that thrombocytopaenia can only be detected at a very low and narrow dose range of PAF (0-75-5-0 ng) in their particular mouse strain, which is 50-300 times lower than the lowest dose reported by O'Neill (1985c) . Other researchers using a Swiss mouse strain have reported that only doses of >^g PAF have the ability to elicit a thrombocytopaenic response when injected i.p. (Amiel et al., 1989) . It is therefore possible that for each of the 5 mouse strains studied the PAF concentrations used were outside the effective dose range.
Both O'Neill (1985c) and Roberts et al. (1987) have demonstrated thrombocytopaenia in preg¬ nant C57BL/6 mice. This is contradictory to our findings and the discrepancy is not due to fewer embryos in the reproductive tract of the mice in our study. One explanation for these conflicting data could be that the inbred line (C57BL/6; no source listed) used by O'Neill and by Roberts et al. (at the same institution) had undergone genetic drifting resulting in subline divergence (Bailey, 1982) .
Another explanation for the failure to observe thrombocytopaenia in either Swiss Webster or C57BL/6 mice during early pregnancy could be the insensitivity of rodent platelets to PAF, as has been described in CD1 mice (Namm et ai, 1982) and rats (Inarrea et ai, 1984) . The present study confirmed PAF insensitivity of isolated CD1 platelets and demonstrated similar PAF insensitivity in platelets isolated from Swiss Webster, BALB/c, C3H/He and C57BL/6 mice using the macro¬ scopic technique of direct observation of platelet aggregation on mirrored plates. Although isolated platelets from all strains of mice tested were insensitive to PAF, they retained their responsiveness to the known platelet-aggregating factors ADP and thrombin, indicating successful platelet iso¬ lation procedures.
It has been suggested that a physiological role for the release of PAF from early embryos is to enhance blastocyst growth due to the release of factors from platelets. This is based on observations that blastocyst outgrowth, the in-vitro equivalent to nidation, occurs only in the presence of whole serum and not with serum derived from platelet-depleted plasma (O'Neill, 1985a; O'Neill et ai, 1989 ). This conclusion is not supported by evidence showing that the products of activated platelets are detrimental to the development of ICR mouse embryos in vitro (Jinno et al., 1987) .
The difficulties of obtaining a mouse strain in which the platelets are sensitive to PAF, com¬ bined with the reported low sensitivity of the bioassay (O'Neill et ai, 1985a; O'Neill, 1987) , make the splenectomized mouse bioassay largely unsuitable for the study of PAF during early pregnancy. Also, recent studies by Amiel et ai (1989) cast some doubt on the ability to forecast embryo viability using the measurement of PAF. In addition to finding embryo-derived PAF production in unfertilized oocytes, they question whether embryo-derived PAF is indeed homologous with PAFacether as claimed by Collier et ai (1988) , as no PAF activity was detected in the very sensitive aggregometry assay, using culture media which had tested positive for embryo-derived PAF using the mouse bioassay. Milligan & Finn (1990) have recently reported that PAF failed to induce decidualization in mice and, contrary to Spinks & O'Neill (1988) , showed that the PAF antagonist was unable to inhibit implantation. Since this study was completed, Smale? al. (1990) have reported their inability to detect PAF production by 2-cell embryos, compact morulae, or blastocysts from C57BL/6J CBA/H mice using either aggregometry or a highly sensitive radioimmunoassay for PAF.
The contradictions among these published reports, together with the present observations of a lack of sensitivity of platelets from several strains of mice to PAF, lead us to conclude that any critical role for PAF in early pregnancy may be less universal and/or more complex than suggested by earlier studies.
